Sort by
Items per page

Send to

Choose Destination

Best matches for EZETIMIBE/TU:

Safety and efficacy of ezetimibe: A meta-analysis. Savarese G et al. Int J Cardiol. (2015)

Ezetimibe-Statin Combination Therapy. Nußbaumer B et al. Dtsch Arztebl Int. (2016)

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition. Kim SH et al. Autophagy. (2017)

Search results

Items: 1 to 20 of 417


Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005 - 2016

Ha D, Lee YJ, Chun Y, Shin JY.

Int J Clin Pharmacol Ther. 2019 Oct;57(10):489-499. doi: 10.5414/CP203374.


Poststatin Lipid Therapeutics: A Review.

Jia X, Lorenz P, Ballantyne CM.

Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32. Review.


[Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies].

Siniawski D, Masson W, Rossi E, Damonte J, Halsband A, Pizarro R.

Medicina (B Aires). 2019;79(2):104-110. Spanish.


Management of dyslipidaemias in the elderly population-A narrative review.

Anagnostis P, Vaitsi K, Veneti S, Georgiou T, Paschou SA, Lambrinoudaki I, Goulis DG.

Maturitas. 2019 Jun;124:93-99. doi: 10.1016/j.maturitas.2019.03.011. Epub 2019 Mar 19. Review.


Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Ma YB, Chan P, Zhang Y, Tomlinson B, Liu Z.

Expert Opin Pharmacother. 2019 Jun;20(8):917-928. doi: 10.1080/14656566.2019.1594776. Epub 2019 Mar 25. Review.


ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.

Ruscica M, Banach M, Sahebkar A, Corsini A, Sirtori CR.

Expert Opin Pharmacother. 2019 May;20(7):791-803. doi: 10.1080/14656566.2019.1583209. Epub 2019 Feb 27.


Combined Effect of Diosgenin Along with Ezetimibe or Atorvastatin on the Fate of Labelled Bile Acid and Cholesterol in Hypercholesterolemic Rats.

Marín-Medina A, Ruíz-Hidalgo G, Blé-Castillo JL, Zetina-Esquivel AM, Zamora RM, Juárez-Rojop IE, Díaz-Zagoya JC.

Int J Environ Res Public Health. 2019 Feb 20;16(4). pii: E627. doi: 10.3390/ijerph16040627.


Efficacy and safety of different doses of alirocumab in reducing low-density lipoprotein cholesterol levels: a network meta-analysis.

Pan R, Li Y, Zhou H.

Pharmazie. 2019 Jan 1;74(1):8-14. doi: 10.1691/ph.2019.8584. Review.


Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials.

Wang X, Luo S, Gan X, He C, Huang R.

Kardiol Pol. 2019;77(2):207-216. doi: 10.5603/KP.a2019.0013. Epub 2019 Feb 11.


Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.

Zhao Z, Du S, Shen S, Luo P, Ding S, Wang G, Wang L.

Medicine (Baltimore). 2019 Feb;98(6):e14400. doi: 10.1097/MD.0000000000014400.


Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.

Khunti K, Danese MD, Kutikova L, Catterick D, Sorio-Vilela F, Gleeson M, Kondapally Seshasai SR, Brownrigg J, Ray KK.

JAMA Netw Open. 2018 Dec 7;1(8):e185554. doi: 10.1001/jamanetworkopen.2018.5554.


Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.

Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chitose T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Hori M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K.

Intern Med. 2018;57(24):3551-3557. doi: 10.2169/internalmedicine.1060-18. Epub 2018 Dec 15.


[Diagnosis and Treatment of Familial Hypercholesterolemia].

Schöb M, Müller P, Gerth Y, Korte W, Rickli H, Brändle M, Bärlocher A, Bilz S.

Praxis (Bern 1994). 2018 Nov;107(24):1345-1353. doi: 10.1024/1661-8157/a003134. Review. German.


Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.

Zhan S, Tang M, Liu F, Xia P, Shu M, Wu X.

Cochrane Database Syst Rev. 2018 Nov 19;11:CD012502. doi: 10.1002/14651858.CD012502.pub2.


Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers.

Wu NQ, Guo YL, Zhu CG, Gao Y, Zhao X, Sun D, Sun J, Xu RX, Liu G, Dong Q, Li JJ.

Lipids Health Dis. 2018 Nov 23;17(1):265. doi: 10.1186/s12944-018-0909-z.


Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.

Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, Parhofer KG.

Eur J Clin Invest. 2019 Feb;49(2):e13053. doi: 10.1111/eci.13053. Epub 2018 Dec 13.


A pilot study of the effect of ezetimibe for postprandial hyperlipidemia.

Xue EZ, Zhang MH, Liu CL.

Medicine (Baltimore). 2018 Nov;97(46):e12960. doi: 10.1097/MD.0000000000012960. Erratum in: Medicine (Baltimore). 2018 Dec;97(52):e13967.


Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.

Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):934-943. doi: 10.1016/S2213-8587(18)30290-0. Epub 2018 Nov 2.


Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria.

Petrov IS, Postadzhiyan AS, Tokmakova MP, Kitova LG, Tsonev SN, Addison J, Petkova RT, Lachev VI.

Folia Med (Plovdiv). 2018 Sep 1;60(3):389-396. doi: 10.2478/folmed-2018-0020.


Supplemental Content

Loading ...
Support Center